Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.

Balic M, Tang G, Rastogi P, Young G, Wallace M, Acosta J, Schneeweiss A, Hilton CJ, Freeman TJ, Li J, Denkert C, Reinisch M, Palomares MR, Arrick BA, Petitt M, Maley SK, Hassan S, Murali S, Boileau JF, Boudreau D, Polewski PJ, Mashru S, Hargis JB, Mortimer J, Thirlwell M, Sikov W, Tan AR, Garces J, Costa G, LoBello J, Mouta J, Darbonne WC, Baehner FL, Mamounas EP, Wolmark N, Loibl S, Geyer CE Jr

Open source

DOI: 10.1200/po-26-00114
Published: 2026 Sep
Container: JCO precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/po-26-00114,
  title = {Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.},
  author = {Balic M and Tang G and Rastogi P and Young G and Wallace M and Acosta J and Schneeweiss A and Hilton CJ and Freeman TJ and Li J and Denkert C and Reinisch M and Palomares MR and Arrick BA and Petitt M and Maley SK and Hassan S and Murali S and Boileau JF and Boudreau D and Polewski PJ and Mashru S and Hargis JB and Mortimer J and Thirlwell M and Sikov W and Tan AR and Garces J and Costa G and LoBello J and Mouta J and Darbonne WC and Baehner FL and Mamounas EP and Wolmark N and Loibl S and Geyer CE Jr},
  year = {2026},
  journal = {JCO precision oncology},
  doi = {10.1200/po-26-00114},
  url = {https://doi.org/10.1200/po-26-00114}
}

RIS

TY  - JOUR
TI  - Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.
AU  - Balic M
AU  - Tang G
AU  - Rastogi P
AU  - Young G
AU  - Wallace M
AU  - Acosta J
AU  - Schneeweiss A
AU  - Hilton CJ
AU  - Freeman TJ
AU  - Li J
AU  - Denkert C
AU  - Reinisch M
AU  - Palomares MR
AU  - Arrick BA
AU  - Petitt M
AU  - Maley SK
AU  - Hassan S
AU  - Murali S
AU  - Boileau JF
AU  - Boudreau D
AU  - Polewski PJ
AU  - Mashru S
AU  - Hargis JB
AU  - Mortimer J
AU  - Thirlwell M
AU  - Sikov W
AU  - Tan AR
AU  - Garces J
AU  - Costa G
AU  - LoBello J
AU  - Mouta J
AU  - Darbonne WC
AU  - Baehner FL
AU  - Mamounas EP
AU  - Wolmark N
AU  - Loibl S
AU  - Geyer CE Jr
PY  - 2026
JO  - JCO precision oncology
DO  - 10.1200/po-26-00114
UR  - https://doi.org/10.1200/po-26-00114
ER  -

APA

M, B., G, T., P, R., G, Y., M, W., J, A., A, S., CJ, H., TJ, F., J, L., C, D., M, R., MR, P., BA, A., M, P., SK, M., S, H., S, M., JF, B., D, B., PJ, P., S, M., JB, H., J, M., M, T., W, S., AR, T., J, G., G, C., J, L., J, M., WC, D., FL, B., EP, M., N, W., S, L., & Jr, G. C. (2026). Evaluation of a Tumor-Informed Molecular Residual Disease Assay in Early Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy, With or Without Atezolizumab.. JCO precision oncology. https://doi.org/10.1200/po-26-00114

Source records

pubmed · retrieved 2026-09-25T22:25:17.383Z